LONDON, Dec. 19, 2012 /PRNewswire/ -- ConvaTec, a world-leading developer of innovative medical technologies, is pleased to announce that the Court of Appeal in the Royal Courts of Justice in the United Kingdom has upheld a previous court's decision validating ConvaTec's patent for its innovative design and manufacturing process for producing silver wound dressings.
This mirrors a similar decision in the European Patent Office last month that ConvaTec's patents for silver wound dressings around Europe are valid.
ConvaTec's AQUACEL® Ag wound dressings include ionic silver, which kills harmful bacteria.
"We were pleased with the original court's decision to uphold our patent and are gratified with this new ruling against Smith & Nephew's appeal," said Ken Berger, CEO. "This ruling recognizes ConvaTec's scientific innovation in the wound care area and the need to protect such work."
ConvaTec's AQUACEL® wound dressings have a gel-forming wound contact layer that promotes healing and protects against infection. The AQUACEL® Ag wound dressing adds ionic silver for even more protection against harmful bacteria.
ConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key focus areas Ostomy Care, Wound Therapeutics, Continence and Critical Care, and Infusion Devices ConvaTec products support healthcare professionals from the hospital to the community health setting. The company has world class manufacturing on nearly every continent and a production network of 12 plants in nine countries. For more information, please visit www.convatec.com.